

IN THE CLAIMS:

Please amend the claims as follows:

Claim 1 (original): A pharmaceutical composition prepared by freeze-drying in vacuo, containing oxaliplatin as the active component and a pharmaceutically acceptable carrier, characterized in that the carrier is at least one alcoholic sugar of non-animal origin, the weight ratio of oxaliplatin to the alcoholic sugar of non-animal origin or alcoholic sugars of non-animal origin being 1:3 to 1:7.

Claim 2 (original): The pharmaceutical composition according to Claim 1, characterized in that it contains oxaliplatin and an alcoholic sugar of non-animal origin or alcoholic sugars of non-animal origin in a weight ratio 1:5.

Claim 3 (previously presented): The pharmaceutical composition according to Claim 1, characterized in that the alcoholic sugar of non-animal origin is mannitol.

Claim 4 (currently amended): A method of manufacturing of pharmaceutical composition according to Claim 1, characterized in that a sterile aqueous solution of oxaliplatin and of at least one alcoholic sugar of non-animal origin, containing oxaliplatin and an alcoholic sugar of non-animal origin or alcoholic sugars of non-animal origin in a weight ratio 1:3 to 1:7, with total concentration of the mentioned compounds 2.8 to 3.2 % by weight, is introduced into a vial in a volume amount ~~equal to at most~~ up to 60 vol% of the available vial volume, whereupon the content of the vial is cooled to a temperature of 2 to 8 °C, then freeze-dried under linear temperature drop of 0.1 to 0.5 °C/min to a final

temperature of -35 to -45 °C, left at this temperature for 1 to 6 hours and then subjected to freeze-drying in vacuo.

Claim 5 (previously presented): The pharmaceutical composition according to Claim 1 for use in the treatment of tumors sensitive to oxaliplatin.